Alteration of the intestinal barrier and GLP2 secretion in Berberine-treated type 2 diabetic rats
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
For centuries, Berberine has been used in the treatment of enteritis in China, and it is also known to have anti-hyperglycemic effects in type 2 diabetic patients. However, as Berberine is insoluble and rarely absorbed in gastrointestinal tract, the mechanism by which it works is unclear. We hypothesized that it may act locally by ameliorating intestinal barrier abnormalities and endotoxemia. A high-fat diet combined with low-dose streptozotocin was used to induce type 2 diabetes in male Sprague Dawley rats. Berberine (100 mg/kg) was administered by lavage to diabetic rats for 2 weeks and saline was given to controls. Hyperinsulinemia and insulin resistance improved in the Berberine group, although there was no significant decrease in blood glucose. Berberine treatment also led to a notable restoration of intestinal villi/mucosa structure and less infiltration of inflammatory cells, along with a decrease in plasma lipopolysaccharide (LPS) level. Tight junction protein zonula occludens 1 (ZO1) was also decreased in diabetic rats but was restored by Berberine treatment. Glutamine-induced glucagon-like peptide 2 (GLP2) secretion from ileal tissue decreased dramatically in the diabetic group but was restored by Berberine treatment. Fasting insulin, insulin resistance index, plasma LPS level, and ZO1 expression were significantly correlated with GLP2 level. In type 2 diabetic rats, Berberine treatment not only augments GLP2 secretion and improves diabetes but is also effective in repairing the damaged intestinal mucosa, restoring intestinal permeability, and improving endotoxemia. Whether these effects are mechanistically related will require further studies, but they certainly support the hypothesis that Berberine acts via modulation of intestinal function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cani, P. D., Possemiers, S., Van de Wiele, T., Guiot, Y., Everard, A., Rottier, O., Geurts, L., Naslain, D., Neyrinck, A., Lambert, D. M., et al. (2009) · Gut · doi:10.1136/gut.2008.165886 · Cited by 2,518 · cited 2×
“For example, GLP2, which is secreted by intestine L cells, is a key regulator of intestinal permeability (Cani et al. 2009).”
BackgroundProtection from obesity-induced insulin resistance in mice lacking TNF-α function
Uysal, K. T., Wiesbrock, S. M., Marino, M. W., & Hotamisligil, G. S. (1997) · Nature · doi:10.1038/39335 · Cited by 2,234 · cited 1×
“The definitive proof of such a connection between inflammatory mediators and insulin resistance in obesity and T2DM came from genetic studies that interfered with inflammatory mediators and demonstrated beneficial effects of this interference on insulin action (Uysal et al. 1997).”
BackgroundZhang, X., Zhao, Y., Zhang, M., Pang, X., Xu, J., Kang, C., Li, M., Zhang, C., Zhang, Z., Zhang, Y., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042529 · Cited by 615
Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice
Membrez, M., Blancher, F., Jaquet, M., Bibiloni, R., Cani, P. D., Burcelin, R. G., Corthesy, I., Macé, K., & Chou, C. J. (2008) · The FASEB Journal · doi:10.1096/fj.07-102723 · Cited by 493 · cited 1×
“plasma LPS and tumor necrosis factor-a levels were decreased in the antibiotic-treated mice, suggesting that modulating gut microbiota ameliorated the inflammatory status in the intestine of the animals (Membrez et al. 2008).”
BackgroundIntestinal growth-promoting properties of glucagon-like peptide-2 in mice
Tsai, C. H., Hill, M., Asa, S. L., Brubaker, P. L., & Drucker, D. J. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.1.e77 · Cited by 319
The gut microbiota ecology: a new opportunity for the treatment of metabolic diseases ?
Burcelin, R. (2009) · Frontiers in Bioscience · doi:10.2741/3589 · Cited by 55
Cited by
Biological properties and clinical applications of berberine
Song, D., Hao, J., & Fan, D. (2020) · Frontiers of Medicine · doi:10.1007/s11684-019-0724-6 · Cited by 496
Berberine pharmacology and the gut microbiota: A hidden therapeutic link
Habtemariam, S. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104722 · Cited by 352
Berberine and inflammatory bowel disease: A concise review
Habtemariam, S. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.09.041 · Cited by 167
Pharmacokinetics and Pharmacological Activities of Berberine in Diabetes Mellitus Treatment
Han, Y., Xiang, Y., Shi, Y., Tang, X., Pan, L., Gao, J., Bi, R., & Lai, X. (2021) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2021/9987097 · Cited by 51
Yang, S., Li, D., Yu, Z., Li, Y., & Wu, M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.709629 · Cited by 40
“Significant reductions in biochemical and morphological markers of diabetes, such as GLP-1 and GLP-2, were also ameliorated after BBR treatment by regulating the microbiota, thereby improving IR and diabetes progression (Shan et al., 2013; Sun et al., 2016).”
Background
Metadata
- Authors
- Shan, C. Y., Yang, J. H., Kong, Y., Wang, X. Y., Zheng, M. Y., Xu, Y. G., Wang, Y., Ren, H. Z., Chang, B. C., & Chen, L. M.
- Venue
- Journal of Endocrinology
- Publisher
- Bioscientifica
- Published
- 2013-06-11
- Volume
- 218
- Issue
- 3
- Pages
- 255-262
- ISSN
- 0022-0795 (ISSN-L)
- 1479-6805
- OpenAlex
- W2147709416
- Cited by
- 58
- References
- 6
- FWCI
- 2.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Alteration of the intestinal barrier and GLP2 secretion in Berberine-treated type 2 diabetic rats. https://app.cochat.ai/papers/10.1530/joe-13-0184
- The paper
- Shan, C. Y., Yang, J. H., Kong, Y., Wang, X. Y., Zheng, M. Y., Xu, Y. G., Wang, Y., Ren, H. Z., Chang, B. C., & Chen, L. M. (2013). Alteration of the intestinal barrier and GLP2 secretion in Berberine-treated type 2 diabetic rats. Journal of Endocrinology. https://doi.org/10.1530/joe-13-0184
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.